Jacobs Levy Equity Management
RYTM icon

Jacobs Levy Equity Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jacobs Levy Equity Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-378,714
Closed -$1.57M – 1143
2022
Q2 		$1.57M Buy
+378,714
New +$2.07M 0.01% 658
2019
Q4 		– Sell
-16,318
Closed -$352K – 1057
2019
Q3 		$352K Buy
+16,318
New +$350K ﹤0.01% 761

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's RYTM Position: Q3 2022 in Review

Jacobs Levy Equity Management sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2022, closing a stake of 378,714 shares — an estimated $1.57M sold.

Jacobs Levy Equity Management first reported a position in RYTM in Q3 2019 and held it in 2 quarters. The position peaked at $1.57M in Q2 2022. 101 funds tracked by Wall St. Rank hold RYTM as of Q3 2022.

  • Jacobs Levy Equity Management reported no remaining Rhythm Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 378,714 Rhythm Pharmaceuticals shares in Q3 2022, an estimated $1.57M.
  • Jacobs Levy Equity Management first reported a position in Rhythm Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Rhythm Pharmaceuticals position peaked at $1.57M in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2022, filed 15 Nov 2022.